We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Emergency Approval of Ebola Test Suggests Opportunity for Test Makers

By LabMedica International staff writers
Posted on 06 Oct 2014
The emergency approval of a real-time PCR test for Zaire Ebolavirus demonstrates the scope of concern about the recent epidemic and a possible opportunity for test makers. More...
The biennial study of the microbiology test product market, “The World Market for Infectious Disease Diagnostic Tests,” by Kalorama Information (New York City, NY, USA) estimated the world market for infectious disease tests at USD 5.3 billion in 2013 and expected it to grow at a slightly higher rate than the rest of the diagnostics market. The scourge of expanding infectious disease threats is part of the factor driving growth of tests. Partly due to the nature of the illness and the high mortality rate (often close to 90% in underdeveloped countries), Ebolavirus disease (EVD) outbreaks can get special international attention from the healthcare community.

Kalorama released its 2013 infectious disease market estimates as the United States Food and Drug Administration (FDA) announced emergency-use-authorization of a TaqMan-based test used by the Department of Defense (DOD). The test was made by the DOD, but is run on instruments from Thermo Fisher Scientific, originally from Carlsbad-based Life Technologies, bought by Thermo Fisher in February 2014. Results of the test, which analyzes blood samples, are available in about 2 hours, whereas other tests take days.

This rare type of emergency authorization by the FDA bypasses the agency's usual approval process. Usually this type of approval is issued during crises, like the current Ebola outbreak in West Africa. "Infectious disease is not an area where governments feel comfortable waiting for test results," said Bruce Carlson, publisher of Kalorama Information, "It's an opportunity for innovative technologies, and test makers who develop solutions in infectious diseases can benefit from the high priority placed on them by healthcare systems."

The Kalorama report covers standard tests for infectious disease, and has breakouts for test technologies and disease categories. Significant efforts in microbiology are detailed in company profiles.

Related Links:

Kalorama Information
The World Market for Infectious Disease Diagnostic Tests 
US FDA Emergency-Use-Authorization of test for Ebola Zaire Virus



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.